Ask Stago

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In this “back to basics” mini-series, Dr LaShanta Brice will discuss the clinical utility of the three most common parameters tested in the lab, the PT, APTT and Fibrinogen. Today we are going to cover the Prothrombin Time! We will discover why an order for a PT would be received by the lab, generally why the PT is used in practice and some emerging trends particularly when considering the INR clinic. Happy listening! Literature source: CLSI H47 One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test     Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, Emily Pullen, North America Product Manager, will tell us more about Stago solution to improve lab productivity with the STA Workcell Max. Literature sources: https://www.stago.com/products-services/max-generation-analysers/sta-workcell-max/ b8e350853878c6885becd8a96ebb5dd8  Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest Dr. Refaai  will help us understand the formation and function of fibrin monomers (FM) in hemostasis, highlighting their crucial role in coagulation and clot formation and the need for more prospective studies to validate this assay for clinical indications such as DIC, VTE and cancer. Literature sources: Refaai M.A. (2018) The Clinical Significance of Fibrin Monomers. Thromb Haemost, 118, 1856. Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation.  In today's episode, Anne-Cécile Ortega will further explain what a MyOptiLab audit is — a service offered by Stago that involves a comprehensive workflow study using the Lean Six Sigma methodology. This audit is designed to help laboratories enhance their efficiency by identifying areas for improvement and optimizing processes.  Literature sources: Bhat, R., & Wagh, P. (2013). "Application of Six Sigma methodology in clinical diagnostic laboratories: A case study."  International Journal of Scientific and Research Publications*, 3(7), 1-6.   Goh, T. N., & Ang, K. S. (2011). "The application of Lean Six Sigma in healthcare."  International Journal of Quality & Reliability Management*, 28(6), 548-564.   Sundararajan, V., & Sharma, P. (2012). "Lean Six Sigma in the clinical laboratory: Achieving improvement in laboratory processes."  Clinical Laboratory Management Review*, 26(2), 82-89.   Kendall, J., & Jones, D. (2017). "The role of Lean Six Sigma in clinical laboratory testing." American Journal of Clinical Pathology*, 147(3), 298-305.   Sofiya, L., & Mirza, M. (2014). "Enhancing diagnostic laboratory performance through Lean Six Sigma." Journal of Healthcare Engineering*, 2014, Article ID 870376, 10 pages.     Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, Karine Carrière  will explain further what are microvesicles, their importance in coagulation and how to analyze them.  Literature sources: [Tesselaar et al.], [Lacroix et al.] [Faille et al.] [Mullier et al.] Vallier et al.] . [Nieuwland et al.] Kim HK, Song KS, Park YS, Kang YH, Lw YJ, Lw KR, et al. Elevated levels of circulating platelet microparticles, VEGF, 11-6 and FiANTES in patients Wlth gastrlc cancer. possible mle of a metastasis predlotor. Eur J Cancer 2003;39(2):184-91. Helley D, Banu E, Bouziane A, Banu A, Scotte F, Fiher AM, et al. Platelet microparticles: a potential predictive factor of survival in hormone-reac pmstate cancer patients treated with docetaxel-based chemotherapy. Eur Urnl2009;56(3):479-84. Zwicker JI, Liebman HA, Neuberg D, Lecmix R, Bauer KA, Furie BC, et ai. Tmr-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15 (22): 68630-40   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. This month we meet Joseph Bautista, is a 37 year old US man living with a rare clotting disorder, a Factor XI deficiency otherwise known as Hemophilia C. His journey so far has not been an easy one but by educating himself and advocating for the best care he is living a full and healthy life working as a data architect in the IT sector. Its an inspiring and reassuring story for anyone facing a rare bleeding disorder diagnosis & proves the importance of patient empowerment.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest Evelyne Escarmant will help us to understand what is behind the recent update of ISO 15189 and what it means for us as manufacturers and indeed the clinical laboratory Literature sources:  ISO 15189; Medical laboratories – Requirements for quality and competence   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest Florence Crépet will help us to understand what is behind the wording “limit of blank”, “limit of detection” and “limit of quantification”, and what it means for the clinical laboratory Literature sources: Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008 Aug;29 Suppl 1(Suppl 1):S49-52. CLSI. Evaluation of Detection Capability for Clinical Laboratory Measurement  Procedures; Approved  Guideline—Second  Edition. CLSI  document EP17-A2. Wayne,  PA: Clinical and Laboratory  Standards Institute; 2012. CLSI Evaluation of Detection Capability Implementation Guide. CLSI Document EP17-Ed2-IG. Wayne, PA: Clinical and Laboratory Standards Institute; 2021.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In this episode, to coincide with International Womens Day (March 8th), we are focusing on Gender equality in the workforce, why this is good for business and good for society overall. We meet with Eva Ohlsson Desormonts, Group HR Director for Stago and Amandine Serret International Business Support and Communications Director for Stago as well as an Executive Coach. Literature sources: Women in the Workpace 2022, McKinsey & Company whitepaper Challenges facing early career women in thrombosis and hemostasis—meeting the needs of the next generation, Guest Editorial, J Thromb Haemost. 2022;20:2453-5455   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, we are delighted to speak to April Matera. April experienced a stroke at the age of 39 and from there began her journey towards an anti-phospholipid syndrome diagnosis. Unfortunately it took 7 different visits to 7 different doctors to get her there. She tells us here about her APS road and how it has impacted her life and her dream to have a family.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In this series of our new season we will be covering Womens' health and looking at the broader implications of coagulation and then speaking to a Lupus patient advocate on the impact this disease has had for her personally. To start off, in today episode, we are delighted to speak to our Clinical Development Director, Dr Francois Depasse about the broader connection between Womens' Health and coagulation and then a more in depth look at APS. Links to related podcasts: S1E13 - Lupus anticoagulant diagnosis work-up https://www.podcastics.com/podcast/episode/13-the-lupus-anticoagulant-diagnosis-work-up-54015/ S3E7 - Hemostasis results interpretation along pregnancy https://www.podcastics.com/podcast/episode/s3e7-hemostasis-results-interpretation-along-pregnancy-134753/ Literature sources: https://www.cdc.gov/ncbddd/blooddisorders/women/facts.html Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306 Devreese KMJ, Ortel TL, Pengo V, de Laat B; Subcommittee on Lupus anticoagulant/Antiphospholipid antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16: 809-813 CLSI Laboratory testing for the Lupus anticoagulant - Approved Guideline. CLSI document H60-A. Wayne, PA; 2014. Devreese, KMJ, de Groot, PG, de Laat, B, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020; 18: 2828– 2839. https://doi.org/10.1111/jth.15047    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest Professor Romaric Lacroix will explain us how fibrinolysis is important to the whole hemostasis process and how the sample fibrinolytic activity needs to be evaluated and sometimes monitored. Link to previous podcasts: S1E15 – Disseminated Intravascular Coagulation (DIC) and fibrin related markershttps://www.podcastics.com/podcast/episode/15-disseminated-intravascular-coagulation-dic-and-fibrin-related-markers-54016/   Literature sources: Cointe S, Vallier L, Esnault P, Dacos M, Bonifay A, Macagno N, Harti Souab K, Chareyre C, Judicone C, Frankel D, Robert S, Hraiech S, Alessi MC, Poncelet P, Albanese J, Dignat-George F, Lacroix R. Granulocyte microvesicles with a high plasmin generation capacity promote clot lysis and improve outcome in septic shock. Blood. 2022 Apr 14;139(15):2377-2391. Cointe S, Harti Souab K, Bouriche T, Vallier L, Bonifay A, Judicone C, Robert S, Armand R, Poncelet P, Albanese J, Dignat-George F et Lacroix R. A new assay to evaluate microvesicle plasmin generation capacity: validation in disease with fibrinolysis imbalance. J Extracell Vesicles 2018; Jul 16;7(1):1494482 Vallier L, Cointe S, Lacroix R, Bonnifay A, Judicone C, Dignat-George F, Hau C. Kwaan. Microparticle and fibrinolysis. Semin Thromb Hemost. 2017 Mar;43(2):129-134   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest Tom Childs will help us to understand the goal and clinical benefits of the Factor parallelism method.   Link to previous podcasts: S1E11 – How to be more productive (part 1): implementation of a rules engine  S2E8 - World Hemophilia Day  S2E4 - How to determine factor levels in hemophilia?  Literature sources: Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program 2006: 432–7 (https://ashpublications.org/hematology/article/2006/1/432/19703/Acquired-Factor-VIII-Inhibitors-Pathophysiology). Morfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008; 14 (Suppl 6): 20–2. Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (7): 2358–63 Monahan PE, Baker JR, Riske B, Soucie JM. Physical functioning in boys with hemophilia in the U.S. Am J Prev Med 2011; 41 (6 Suppl 4): S360–8. Collins PW, Chalmers E, Hart D et al.; United Kingdom Haemophilia Centre Doctors' Organization. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol 2013; 162 (6): 758–73 (https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.12463). Riley PW, Gallea B, Valcour A. Development and implementation of a coagulation factor testing method utilizing autoverification in a high‑volume clinical reference laboratory environment. J Pathol Inform 2017; 8: 25. Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4 (1): 59–72 Oldenburg J, Mahlangu JN, Kim B et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (9): 809–18. Florin L, Desloovere M, Devreese KML. Validation of an automated algorithm for interpretation of lupus anticoagulant testing on the Stago STA R Max (Poster). International Society on Thrombosis and Haemostasis, 2017.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest Gabrielle Pearl will explain us the particularities of thrombosis and hemostasis in pediatric population, and how to manage pediatric patient samples in the clinical laboratory. Link to previous podcasts: S2E5 - How to collect and prepare the coagulation samples properly? S2E3 - How to establish and control the reference range of my assay?   Literature sources: Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, De Rosa L, Hamilton S, Ragg P, Robinson S, Auldist A, Crock C, Roy N, Rowlands S. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006 Feb;95(2):362-72. doi: 10.1160/TH05-01-0047. Monagle P, Massicotte P. Developmental haemostasis: secondary haemostasis. Semin Fetal Neonatal Med. 2011 Dec;16(6):294-300. doi: 10.1016/j.siny.2011.07.007. Attard C, van der Straaten T, Karlaftis V, Monagle P, Ignjatovic V. Developmental hemostasis: age-specific differences in the levels of hemostatic proteins. J Thromb Haemost 2013; 11: 1850–4. Flanders MM, Phansalkar AR, Crist RA, Roberts WL, Rodgers GM. Pediatric reference intervals for uncommon bleeding and thrombotic disorders. J Pediatr. 2006 Aug;149(2):275-7. doi: 10.1016/j.jpeds.2006.04.008 Lippi G, Franchini M, Montagnana M, Guidi GC. Coagulation testing in pediatric patients: the young are not just miniature adults. Semin Thromb Hemost. 2007 Nov;33(8):816-20. doi: 10.1055/s-2007-1000373.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis. In today episode, our expert Lydie Nicoud, R&D reagent manager, will talk with us about the test of fibrinogen.  As usual, don't forget to send any question you may have to ask@stago.com, we will be glad to answer to it. Literature sources: Miesbach W, Schenk J, Alesci S, Lindhoff-Last E, Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia .Thromb Res. 2010; 126(6): e428-33 Karapetian H. Reptilase time (RT). Methods Mol Bio 2013; 992:273-7. Mackie IJ, Kitchen S, Machin SJ, Lowe GDO, Guidelines on fibrinogen assays, Br J Hematol 2003; 121: 396-404 Cunningham MT, Olson JD, Chandler WL, Van Cott EM, Eby CS, Teruya J, Hollensead SC, Adcock DM, Allison PM, Kottke-Marchant KK, Smith MD. External quality assurance of fibrinogen assays using normal plasma: results of the 2008 College of American Pathologists proficiency testing program in coagulation. Arch Pathol Lab Med. 2012 Jul;136(7):789-95. doi: 10.5858/arpa.2011-0322-OA. PMID: 22742551.Siriez R, Dogné JM, Gosselin R, Laloy J, Mullier F, Douxfils J Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: practical recommendations for the laboratory. Int J Lab Hematol 2021; 43(1): 7-20   Related podcasts: S1E9: How to manage HIL samples in the coagulation laboratory?  S1E15: Disseminated Intravascular Coagulation (DIC) and fibrin related markers.  S2E6: Prothrombin Time routine does not mean "simple".    S2E7: APTT, not a one-for-all purposes reagent.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation.   In today's episode, our guest Dr Bryan G Fry, aka Venom Doc, will make us enter his world and understand how venom interact with coagulation and how they can prove useful for assay or drug design & development     Literature sources: Fry BG, Roelants K, Champagne DE, Scheib H, Tyndall JD, King GF, Nevalainen TJ, Norman JA, Lewis RJ, Norton RS, Renjifo C, de la Vega RC. The toxinogenomic multiverse: convergent recruitment of proteins into animal venoms. Annu Rev Genomics Hum Genet. 2009, 10: 483-511. Bittenbinder, M. A., C. N. Zdenek, B. Op den Brouw, N. J. Youngman, J. S. Dobson, A. Naude, F. J. Vonk and B. G. Fry (2018). "Coagulotoxic Cobras: Clinical Implications of Strong Anticoagulant Actions of African Spitting Naja Venoms That Are Not Neutralised by Antivenom but Are by LY315920 (Varespladib)." Toxins (Basel) 10(12): 516. Chowdhury, A., M. R. Lewin, C. N. Zdenek, R. Carter and B. G. Fry (2021a). "The Relative Efficacy of Chemically Diverse Small-Molecule Enzyme-Inhibitors Against Anticoagulant Activities of African Spitting Cobra (Naja Species) Venoms." Front Immunol 12: 752442. Seneci, L., C. N. Zdenek, A. Chowdhury, C. F. B. Rodrigues, E. Neri-Castro, M. Benard-Valle, A. Alagon and B. G. Fry (2021). "A Clot Twist: Extreme Variation in Coagulotoxicity Mechanisms in Mexican Neotropical Rattlesnake Venoms." Front Immunol 12: 612846. Chowdhury, A., C. N. Zdenek, J. S. Dobson, L. A. Bourke, R. Soria and B. G. Fry (2021b). "Clinical implications of differential procoagulant toxicity of the palearctic viperid genus Macrovipera, and the relative neutralization efficacy of antivenoms and enzyme inhibitors." Toxicol Lett 340: 77-88. Chowdhury, A., C. N. Zdenek, M. R. Lewin, R. Carter, T. Jagar, E. Ostanek, H. Harjen, M. Aldridge, R. Soria, G. Haw and B. G. Fry (2021). "Venom-Induced Blood Disturbances by Palearctic Viperid Snakes, and Their Relative Neutralization by Antivenoms and Enzyme-Inhibitors." Frontiers in Immunology 12: 2251. Zdenek, C. N., B. O. den Brouw, D. Dashevsky, A. Gloria, N. Youngman, E. Watson, P. Green, C. Hay, N. Dunstan, L. Allen and B. G. Fry (2019a). "Clinical implications of convergent procoagulant toxicity and differential antivenom efficacy in Australian elapid snake venoms." Toxicol Lett 316: 171-182. Zdenek, C. N., C. Hay, K. Arbuckle, T. N. W. Jackson, M. H. A. Bos, B. Op den Brouw, J. Debono, L. Allen, N. Dunstan, T. Morley, M. Herrera, J. M. Gutierrez, D. J. Williams and B. G. Fry (2019b). "Coagulotoxic effects by brown snake (Pseudonaja) and taipan (Oxyuranus) venoms, and the efficacy of a new antivenom." Toxicol In Vitro 58: 97-109. Sousa, L. F., C. A. Nicolau, P. S. Peixoto, J. L. Bernardoni, S. S. Oliveira, J. A. Portes-Junior, R. H. Mourao, I. Lima-dos-Santos, I. S. Sano-Martins, H. M. Chalkidis, R. H. Valente and A. M. Moura-da-Silva (2013). "Comparison of phylogeny, venom composition and neutralization by antivenom in diverse species of bothrops complex." PLoS Negl Trop Dis 7(9): e2442. Rogalski, A., C. Soerensen, B. Op den Brouw, C. Lister, D. Dashevsky, K. Arbuckle, A. Gloria, C. N. Zdenek, N. R. Casewell, J. M. Gutierrez, W. Wuster, S. A. Ali, P. Masci, P. Rowley, N. Frank and B. G. Fry (2017). "Differential procoagulant effects of saw-scaled viper (Serpentes: Viperidae: Echis) snake venoms on human plasma and the narrow taxonomic ranges of antivenom efficacies." Toxicol Lett 280: 159-170. Youngman, N. J., J. Llinas and B. G. Fry (2021). "Evidence for Resistance to Coagulotoxic Effects of Australian Elapid Snake Venoms by Sympatric Prey (Blue Tongue Skinks) but Not by Predators (Monitor Lizards)." Toxins (Basel) 13(9).   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest François Depasse will help us to understand the hemostasis results obtained along pregnancy, what are the related difficulties for the lab and Link to previous podcasts: S1E15 Disseminated Intravascular Coagulation (DIC) and fibrin related markers: S2E1 Whole Blood Viscoelastic Testing (VET) Literature sources: Szecsi PB, Jørgensen M, Klajnbard A, Andresen MR, Colov NP, Stender S, Haemostatic reference intervals in pregnancy. Thromb Haemost 2010; 2013: 718-27 Kristoffersen AH, Peters PH, Bjørge L, Røraas T and Sandberg S. Concentration of fibrin monomer in pregnancy and during the postpartum period. Annals of Clinical Biochemistry 2019; 56(6): 692-700. Hellgren H. Hemostasis during normal prgenancy and puerperium. Semin Thromb Hemost. 2003; 29(2): 125-30. Leduc L, Wheeler JM, Kirshon B, Mitchell P, Cotton DB, Coagulation profile in severe preeclampsia, Obstet Gynecol 1992 79(1); 14-8 Gillissen A, van den Akker T, Caram-Deelder C, Henriquez DDCA, Bloemenkamp KWM, de Maat MPM, van Roosmalen JJM, Zwart JJ, Eikenboom J, van der Bom JG. Coagulation parameter during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study. Blood Adv 2018; 2(19): 2433-42 Ducloy-Bouthors AS, Mercier FJ, Grouin JM, Bayoumey F, Corouge I, Le Goueze A, Rackelboom T, Broisin F, Vial F, Luzi A, Capronnier O, Huissoud C, Mignon A, Early and systematic administration of fibrinogen concentrate in post-partum haemorrhage following vaginal delivery: the FIDEL randomized controlled trial. BJOG 2021. 128:1814-23. Brenner A, Ker K, Shakur-Still H, Roberts I. Tranexamic acid for post-partum haemorrhage: what, who and when. Best Pract Res Clin Obstet Gynaecol. 2019; 1:66-74   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest Sophie Réhault will give us explanations on what is the new EU IVD regulation and what it implies both for IVD manufacturers and for the clinical laboratories.  Link to previous podcasts:  S2E18 – Practical check list of the implementation of an instrument in your lab:  S3E4 – All you need to know about instrument validation:    Literature sources: Regulation (EU) 2017/746 (IVDR) of the Europan Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and commission Decision 2010/227/EU European Parliament Legislative resolution of 15 December 2021 on te proposal for a regulation of the European Parliament and of the Council amending Regulation (EU) 2017/746 as regards transitional provisions for certain in vitro diagnostic medical devices and deferred application of requirements for in house devices (COM(2021) 0627-C9-0381/2021 – 2021/0323 (COD))   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest Daniel Pilbeam, from the Clinical Pathology Laboratory at UVet in Melbourne will help us understand the common points and differences between veterinary and human hemostasis, and what should be critically assessed.   Previous episodes in relation to the topic:  AskStago episode #9 (season 1): How to manage HIL samples in the coagulation laboratory?   Literature sources: John W. Harvey, Veterinary Hematology, Chapter 7 - Evaluation of Hemostasis: Coagulation and Platelet Disorders, W.B. Saunders, 2012, Pages 191-233, ISBN 9781437701739, https://doi.org/10.1016/B978-1-4377-0173-9.00007-5. Beurlet S, Coisnon C, Nguyen TT, Richet M, Carlo A, Briend-Marchal A. Comparison of STA-NeoPTimal (Stago) and STA-Neoplastine CI Plus (Stago) thromboplastin reagents using a STA Satellite Max analyzer to measure prothrombin times in dogs. Vet Clin Pathol. 2021 Sep;50(3):348-353. doi: 10.1111/vcp.12949. A previous pathologist, Bruce Parry, also co-wrote a paper that was instrumental in identifying cut offs for factor deficiencies that we still use the reference range for today.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our guest Kaitlyn Pelc will explain further the different steps to validate an instrument at the installation. Previous episodes in relation to the topic: S2E18 – Practical check list of the implementation of an instrument in your lab: https://www.podcastics.com/podcast/episode/s2e18-practical-check-list-of-the-implementation-of-an-instrument-in-your-lab-103649/ S2E3 – How to establish and control the reference range of my assay: https://www.podcastics.com/podcast/episode/s2e3-how-to-establish-and-control-the-reference-range-of-my-assay-60155/ S2E2 - How to calibrate your reagent as a pro: https://www.podcastics.com/podcast/episode/s2e2-how-to-calibrate-your-reagent-as-a-pro-58249/ Literature sources: CLSI. Protocol for the Evaluation, Validation and Implementation of Coagulometers; Approved Guideline. CLSI document H57-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. CLSI. One-Stage Prothrombin Time (PT-Test and Activated Partial Thromboplastin Time (APTT) Test; Approved Guideline- Second Edition. CLSI document H47-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. CLSI. Procedures for Validation of INR and Local Calibration of PT/INR Systems; Approved Guideline. CLSI document H54-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline- Third Edition. CLSI document EP28-A3c. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. CLSI. Measurement Procedure Comparison and Bias Estimation Using Patient Samples. 3rd ed. CLSI guideline EP09c. Wayne, PA: Clinical and Laboratory Standards Institute; 2018. CLSI. User Verification of Precision and Estimation of Bias; Approved Guideline- Third Edition. CLSI document EP15-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2014. College of American Pathologists.  All Common Checklist. Northfield, IL: College of American Pathologists; 2021.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis. In today's episode, our guest David Courtois will explain further what is platelet aggregometry, how to measure it and in which indications it is useful.   Literature sources: Born GVR. Aggregation of blood platelets by adenosine disphosphate and its reversal. Nature 1962; 194: 927 – 929. O'Brien JR. Platelet aggregation. II. Some results from a new method of study. J Clin Pathol 1962; 15: 452-458. Caen JP, Michel H. Platelet shape change and aggregation. Nature 1972; 240 (5377): 148-149. Holmsen H. Platelet metabolism and activation Semin Hematol. 1985; 22 (3): 2 19-40. Kinlough-Rathbone RL, Packham MA, Mustard JF. Platelet aggregation in Methods in Hematology, Churchill Livingstone, New-York 1983; 8: 64-91. Zhou L, Schmaier AH. Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol 2005; 123 (2): 172-183. Hvas AM, Favaloro EJ. Platelet function analyzed by light transmission aggregometry. Methods Mol Biol 2017; 1646: 321-331. Christie DJ, Avari T, Carrington LR, Cohen E, DeBiase BA, Harrison P, Kickler TS, Kottke-Marchant K, Ledford-Kraemer M, Rand ML, Schmaier AH, McCabe White M. Platelet function testing by aggregometry: approved guidelines, H58-A. Clinical and Laboratory Standards Institute: Wayne, PA, USA 2008; 28 (31): 1-45. Frontroth, J.P.; Favaloro, E.J. Ristocetin-Induced Platelet Aggregation (RIPA) and RIPA Mixing Studies. Methods Mol. Biol. 2017, 1646, 473–494. Hayward CPM, Pai M, Liu Y, Moffat KA, Seecharan J, Weber KE, Cook RJ, Heddle NM. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorders assessments. J Throm Haemost 2009; 7 (4): 676-684 Cattaneo M., Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSCC of the ISTH. J. Thromb Haemost 2009; 7: 1029 Hayward CPM, Moffat KA, Raby A, Israels S, Plumhoff E, Flynn G, Zehnder J.L. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol 2010; 134: 955-963. Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, Machin S. British Committee for Standards in Haematology. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011; 155: 30-44 Dawood BB, Lowe GC, Lordkipanidze M, Bem D, Daly ME, Makris M, Mumford A, Wilde JT, Watson SP. Evaluation of participants with suspected heritable platelet function disorder including recommendation and validation of a streamlined agonist panel. Blood 2012; 120 (25): 5041-5049. Cattaneo M, Cerletti C, Harrison P, Hayward CPM, Kenny D, Nugent D, Nurden P, Rao KA, Schmaier AH, Watson SP, Lussana F, Pugliano MT. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Throm Haemost 2013; 11: 1183-1189. Rao AK. Inherited platelet function disorders: overview and disorders of granules, secretion, and signal transduction. Hematol Oncol Clin North Am 2013; 27 (3): 585-611. Nurden AT, Nurden P. Inherited disorders of platelet function: selected updates. J Thromb Haemost 2015; 13 (Suppl 1): 2-9. Frelinger AL 3rd, Gachet C, Mumford AD, Noris P, Mezzano D, Harrison P, Gresele P. Laboratory monitoring P2Y12 inhibitors communication from the SSC of the ISTH. J Throm Haemost 2018; 16 (11): 2341-2346 Podda G, Scavone M, Femia EA, Cattaneo M. Aggregometry in the settings of thrombocytopenia, thrombocytosis and antiplatelet therapy. Platelets 2018; 29 (7): 644-649. Hayward CPM, Moffat KA, Brunet J, Carlino SA, Plumhoff E, Meijer P, Zehnder JL. Update on diagnostic testing for platelet function disorders: What is pratical and useful? Int J Lab Hematol 2019; 41 (Suppl 1): 26-32 Gresele P, Orsini S, Noris P, Falcinelli E, Alleci MC, Bury L, Borhany M, Santoro C, Glembotsky AC, Cid AR, Tosetto A, De Candia E, Fontan P, Guglielmini G, Pecci A, BAT-VAL study investigators (57). Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. J Thromb Haemost 2020; 18 (3): 732:739. Rabbolini D, Connor D, Morel-Kopp MC, Donikian D, Kondo M, Chen W, Alessi MC, Stevenson W, Chen V, Joseph J, Brighton C, Ward C, Sydney Platelet Group. An integrated approach to inherited platelet disorders: results from a research collaborative, the Sydney Platelet Group. Pathology 2020; 52 (2): 243-255.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis. In today episode, our expert Charlotte Parent, Marketing product manager, will talk with us about the EQA. A valuable tool to ensure the quality of laboratory results. As usual, don't forget to send any question you may have to ask@stago.com, we will be glad to answer to it.   Literature sources: Ask Stago season 1 episode 3: eIQC and EQA: benefits and differences  https://www.podcastics.com/podcast/episode/3-eiqc-and-eqa-benefits-and-differences-35848/ ISO 15189:2012, Medical laboratories — Requirements for quality and competence ISO 13528:2015 Statistical methods for use in proficiency testing by interlaboratory comparison   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis. In today episode, our expert guest, Dr Caroline Vayne from Tours University Hospital in France, gives us an overview on heparin induced thrombocytopenia. As usual, don't forget to send any question you may have to ask@stago.com, we will be glad to answer to it.   Learn more: Gruel Y, Vayne C, Rollin J, Weber P, Faille D, Bauters A, Macchi L, Alhenc-Gelas M, Lebreton A, De Maistre E, Voisin S, Gouilleux-Gruart V, Perrin J, Tardy-Poncet B, Elalamy I, Lavenu-Bombled C, Mouton C, Biron C, Ternisien C, Nedelec-Gac F, Duchemin J, De Raucourt E, Gouin-Thibault I, Rugeri L, Tardy B, Giraudeau B, Bejan-Angoulvant T, Pouplard C. Comparative Analysis of a French Prospective Series of 144 Patients with Heparin-Induced Thrombocytopenia (FRIGTIH) and the Literature. Thromb Haemost. 2020 Jul;120(7):1096-1107. doi: 10.1055/s-0040-1712957. Epub 2020 Jun 22. PMID: 32572863. Gruel Y, De Maistre E, Pouplard C, Mullier F, Susen S, Roullet S, Blais N, Le Gal G, Vincentelli A, Lasne D, Lecompte T, Albaladejo P, Godier A; Members of the French Working Group on Perioperative Haemostasis Groupe d'intérêt en hémostase périopératoire GIHP. Diagnosis and management of heparin-induced thrombocytopenia. Anaesth Crit Care Pain Med. 2020 Apr;39(2):291-310. doi: 10.1016/j.accpm.2020.03.012. Epub 2020 Apr 13. PMID: 32299756. Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017 May 25;129(21):2864-2872. doi: 10.1182/blood-2016-11-709873. Epub 2017 Apr 17. PMID: 28416511; PMCID: PMC5445568. Rollin J, Pouplard C, Gruel Y. Risk factors for heparin-induced thrombocytopenia: Focus on Fcγ receptors. Thromb Haemost. 2016 Oct 28;116(5):799-805. doi: 10.1160/TH16-02-0109. Epub 2016 Jun 30. PMID: 27358188. Pishko AM, Cuker A. Diagnosing heparin-induced thrombocytopenia: The need for accuracy and speed. Int J Lab Hematol. 2021 Jul;43 Suppl 1:96-102. doi: 10.1111/ijlh.13564. PMID: 34288442. Tardy B, Lecompte T, Mullier F, Vayne C, Pouplard C. Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia. J Clin Med. 2020 Apr 24;9(4):1226. doi: 10.3390/jcm9041226. PMID: 32344682; PMCID: PMC7230370. Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, Linkins LA, Rodner SB, Selleng S, Warkentin TE, Wex A, Mustafa RA, Morgan RL, Santesso N. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018 Nov 27;2(22):3360-3392. doi: 10.1182/bloodadvances.2018024489. PMID: 30482768; PMCID: PMC6258919. Vayne C, Rollin J, Gruel Y, Pouplard C, Galinat H, Huet O, Mémier V, Geeraerts T, Marlu R, Pernod G, Mourey G, Fournel A, Cordonnier C, Susen S. PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia. N Engl J Med. 2021 Jul 22;385(4):376-378. doi: 10.1056/NEJMc2106383. Epub 2021 May 19. PMID: 34010527; PMCID: PMC8174029. Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, Rampotas A, Ambler G, Makris M. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. N Engl J Med. 2021 Oct 28;385(18):1680-1689. doi: 10.1056/NEJMoa2109908. Epub 2021 Aug 11. PMID: 34379914. Kizlik-Masson C, Vayne C, McKenzie SE, Poupon A, Zhou Y, Champier G, Pouplard C, Gruel Y, Rollin J. 5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies. J Thromb Haemost 2017; 15: 2065–75. Related podcast: Understand the sensitivity and specificity https://www.podcastics.com/podcast/episode/8-what-are-sensitivity-and-specificity-performances-of-a-diagnostic-assay-37747/   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today's episode, our co-host Audrey Carlo will share her understanding on what is HTA and why Value of Diagnostic Information should be further recognized. Literature sources: Wurcel V, Cicchetti A, Garrison L, Kip MMA, Koffijberg H, Kolbe A, Leeflang MMG, Merlin T, Mestre-Ferrandiz J, Oortwijn W, Oosterwijk C, Tunis S, Zamora B. The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems. Public Health Genomics. 2019;22(1-2):8-15. doi: 10.1159/000501832. Proposal for a Regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU.  Porter ME, Teisberg EO, Redefining Health Care: Creating Value-based Competition on Results, Boston, Mass. : Harvard Business School Press, ©2006.   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation.  In today's episode, our expert Pauline Vasselon, US & Projects Registration Coordinator within Stago Market Access team, will provide us the key steps to implement a new instrument in your laboratory.    Literature sources:  ISO 15189 Medical laboratories — Requirements for quality and competence  ISO 22870:2010 Intelligent transport systems — Devices to aid reverse manoeuvres — Extended-range backing aid systems (ERBA)  CLSI Measurement Procedure Comparison and Bias Estimation Using Patient Samples, 3rd Edition, CLSI document EP09c, Wayne PA, 2018.  CLSI Evaluation of Precision of Quantitative Measurement Procedures, Approved guideline, 3rd Edition CLSI document EP05-A3, Wayne PA, 2014.  CLSI Evaluation of Linearity of Quantitative Measurement Procedures, 2nd edition, CLSI document EP06, Wayne PA, 2020.  CLSI Protocol for the Evaluation, Validation, and Implementation of Coagulometers, Approved Guideline, CLSI document H57-A, Wayne PA, 2008.    Related podcasts:   Uncertainty of measurement - Manage lot conversion - Manage your pre-analyticals - Control the reference ranges of your method - Manage HIL interferences - Understand the sensitivity and specificity - Calculate your MNPT -    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis. In today episode, our expert guest, Dr Stephan Moll, will give a hint of his webinar entitled “The Patient with Venous Thrombosis – Practical Points for the Laboratorian and the Clinician”. As usual, don't forget to send any question you may have to ask@stago.com, we will be glad to answer to it. Learn more: Detailed DVT/PE brochure for patients: Moll S, Waldron B. DVT and PE: Information for newly diagnosed patients. Clot Connect brochure for patients. https://clotconnect.wpcomstaging.com/wp-content/uploads/2020/03/dvt_and_pe.pdf Condensed DVT/PE information for patients: Waldron B, Moll S. Guide to recovery after deep vein thrombosis or pulmonary embolism. Circulation 2014;129:e477-e479. Link to Dr Moll's webinar:  hhttps://www.labroots.com/ms/webinar/patient-venous-thrombosis-practical-laboratorian-clinician   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis.  In today episode, our expert guest, Jonathan Douxfils, CEO at QUALIblood SA and Professor at the University of Namur / Department of Pharmacy, will detail with us the current recommendation on how to measure direct oral anticoagulants and in which clinical situation this information is relevant and useful..   As usual, don't forget to send any question you may have to ask@stago.com, we will be glad to answer to it.  Learn more - Literature sources:  Bernier M, Lancrerot SL, Parassol N, Lavrut T, Viotti J, Rocher F, Drici MD. Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio. J Cardiovasc Pharmacol. 2020 Oct;76(4):472-477. Epub 2020/10/09. doi:10.1097/FJC.0000000000000870. Cited in: Pubmed; PMID 33030858.  Douxfils J, Ageno W, Samama CM, Lessire S, Ten Cate H, Verhamme P, Dogne JM, Mullier F. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. Journal of thrombosis and haemostasis : JTH. 2018 Feb;16(2):209-219. Epub 2017/12/02. doi:10.1111/jth.13912. Cited in: Pubmed; PMID 29193737.  Douxfils J, Mullier F, Dogne JM. Dose tailoring of dabigatran etexilate: obvious or excessive? Expert Opin Drug Saf. 2015 Aug;14(8):1283-9. Epub 2015/05/23. doi:10.1517/14740338.2015.1049995. Cited in: Pubmed; PMID 25994994.  Gosselin RC, Adcock DM, Bates SM, Douxfils J, Favaloro EJ, Gouin-Thibault I, Guillermo C, Kawai Y, Lindhoff-Last E, Kitchen S. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thrombosis and haemostasis. 2018 Mar;118(3):437-450. Epub 2018/02/13. doi:10.1055/s-0038-1627480. Cited in: Pubmed; PMID 29433148.  Gosselin RC, Adcock DM, Douxfils J. An update on laboratory assessment for direct oral anticoagulants (DOACs). International journal of laboratory hematology. 2019 May;41 Suppl 1(00):33-39. Epub 2019/05/10. doi:10.1111/ijlh.12992. Cited in: Pubmed; PMID 31069969.  Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment. Journal of thrombosis and haemostasis : JTH. 2016 Dec;14(12):2556-2559. Epub 2016/10/25. doi:10.1111/jth.13505. Cited in: Pubmed; PMID 27622661.  Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply. Journal of thrombosis and haemostasis : JTH. 2016 Dec;14(12):2559-2561. Epub 2016/10/25. doi:10.1111/jth.13513. Cited in: Pubmed; PMID 27662099.  Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures. Journal of thrombosis and haemostasis : JTH. 2016 Jul;14(7):1325-7. Epub 2016/04/21. doi:10.1111/jth.13344. Cited in: Pubmed; PMID 27094864  Douxfils J, Adcock DM, Bates SM, Favaloro EJ, Gouin-Thibault I, Guillermo C, Kawai Y, Lindhoff-Last E, Kitchen S, Gosselin RC. 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thrombosis and haemostasis. 2021 Mar 19. Epub 2021/03/21. doi:10.1055/a-1450-8178. Cited in: Pubmed; PMID 33742436.  Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L, Investigators R-L. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). Journal of the American College of Cardiology. 2014 Feb 4;63(4):321-8. Epub 2013/10/01. doi:10.1016/j.jacc.2013.07.104. Cited in: Pubmed; PMID 24076487.  Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. The Lancet. 2015;385(9984):2288-2295. doi:10.1016/s0140-6736(14)61943-7.  Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. JAMA Cardiol. 2017 May 1;2(5):566-574. Epub 2017/03/30. doi:10.1001/jamacardio.2017.0364. Cited in: Pubmed; PMID 28355459.  Bouget J, Oger E. Emergency admissions for major haemorrhage associated with direct oral anticoagulants. Thrombosis research. 2015 Dec;136(6):1190-4. Epub 2015/11/08. doi:10.1016/j.thromres.2015.10.036. Cited in: Pubmed; PMID 26545315.  Pollack CV, Jr., Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. The New England journal of medicine. 2017 Aug 3;377(5):431-441. Epub 2017/07/12. doi:10.1056/NEJMoa1707278. Cited in: Pubmed; PMID 28693366.  Sennesael AL, Larock AS, Douxfils J, Elens L, Stillemans G, Wiesen M, Taubert M, Dogne JM, Spinewine A, Mullier F. Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thrombosis journal. 2018;16:28. Epub 2018/11/21. doi:10.1186/s12959-018-0183-3. Cited in: Pubmed; PMID 30455596.  Testa S, Legnani C, Antonucci E, Paoletti O, Dellanoce C, Cosmi B, Pengo V, Poli D, Morandini R, Testa R, Tripodi A, Palareti G, Coordinator of SR. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. Journal of thrombosis and haemostasis : JTH. 2019 Jul;17(7):1064-1072. Epub 2019/04/24. doi:10.1111/jth.14457. Cited in: Pubmed; PMID 31013383.  Testa S, Paoletti O, Legnani C, Dellanoce C, Antonucci E, Cosmi B, Pengo V, Poli D, Morandini R, Testa R, Tripodi A, Palareti G. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. Journal of thrombosis and haemostasis : JTH. 2018 May;16(5):842-848. Epub 2018/03/14. doi:10.1111/jth.14001. Cited in: Pubmed; PMID 29532628.  Suwa M, Morii I, Kino M. Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation- Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration. Circ J. 2019 Apr 25;83(5):991-999. Epub 2019/03/29. doi:10.1253/circj.CJ-18-1282. Cited in: Pubmed; PMID 30918237.  Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidbuchel H, External r, Lip GYH, Deneke T, Dagres N, Boriani G, Chao TF, Choi EK, Hills MT, Santos IS, Lane DA, Atar D, Joung B, Cole OM, Field M. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2021 Apr 25. Epub 2021/04/26. doi:10.1093/europace/euab065. Cited in: Pubmed; PMID 33895845.  Seiffge DJ, Traenka C, Polymeris AA, Thilemann S, Wagner B, Hert L, Muller MD, Gensicke H, Peters N, Nickel CH, Stippich C, Sutter R, Marsch S, Fisch U, Guzman R, De Marchis GM, Lyrer PA, Bonati LH, Tsakiris DA, Engelter ST. Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice. J Stroke. 2017 Sep;19(3):347-355. Epub 2017/09/08. doi:10.5853/jos.2017.00395. Cited in: Pubmed; PMID 28877563.  Steiner T, Bohm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, Riess H, Rother J, Schellinger PD, Spannagl M, Veltkamp R. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol. 2013 Jun;102(6):399-412. Epub 2013/05/15. doi:10.1007/s00392-013-0560-7. Cited in: Pubmed; PMID 23669868.  Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI, Subcommittee on Control of A. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. Journal of thrombosis and haemostasis : JTH. 2016 Mar;14(3):623-7. Epub 2016/02/26. doi:10.1111/jth.13227. Cited in: Pubmed; PMID 26911798.  Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. Journal of thrombosis and haemostasis : JTH. 2016 Jun;14(6):1308-13. Epub 2016/06/15. doi:10.1111/jth.13323. Cited in: Pubmed; PMID 27299806.  Piran S, Traquair H, Chan N, Bhagirath V, Schulman S. Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. Res Pract Thromb Haemost. 2018 Oct;2(4):684-688. Epub 2018/10/24. doi:10.1002/rth2.12146. Cited in: Pubmed; PMID 30349887.  Siriez R, Dogne JM, Gosselin R, Laloy J, Mullier F, Douxfils J. Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory. International journal of laboratory hematology. 2021 Feb;43(1):7-20. Epub 2020/09/19. doi:10.1111/ijlh.13342. Cited in: Pubmed; PMID 32946681.    Qualiblood website: https://www.qualiblood.eu Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice. 

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in haemostasis.  In today episode, our expert Arnaud Rouvière, Global process – Service manager, will provide us all the current recommendations to establish your Quality control ranges.   As usual, don't forget to send any question you may have to ask@stago.com, we will be glad to answer to it.    Learn more  - Previous mentioned podcast  : Previous episode with Arnaud Rouvière : S1E7 How to determine the mean normal prothrombin time  Learn more about the externalization of your Internal quality controls (eIQC) : S1E3 #3 eIQC and EQA: benefits and differences   Go further with the episode dedicated to the reagent lot conversion : S2E10 - How to manage lot conversion in your daily lab management?  Literature sources:  CLSI Statistical Quality Control for Quantitative Measurement Procedures: Principles and definitions; 4th ed. CLSI guideline C24. Wayne PA: Clinical and Laboratory Standard Institute, 2016.  ISO 15189:2012 – Meical laboratories – requirements for quality and competence  College of American Pathologists. All Common Checklist. Northfield, IL: College of American Pathologists; 2020  Neufassung der Richtlinie der Bundesärztekammer zur Qualitätssicherung laboratoriumsmedizinischer Untersuchungen; Rili-BÄK; – Richtlinie der Bundesärztekammer zur Qualitätssicherung laboratoriumsmedizinischer Untersuchungen. Dtsch Arztebl Int 2014;111:1583–618. English version: Revision of the “Guideline of the German Medical Association on Quality Assurance in Medical laboratory Examinations – Rili-BAEK”. J Lab Med 2015;39:26–69  Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice. 

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis.  In today episode, our expert guest, Laure Morimont, Project leader at QUALIblood SA, will detail with us the current knowledge on thrombotic risk under hormonal therapy and how this can be assessed.    As usual, don't forget to send any question you may have to ask@stago.com, we will be glad to answer to it.  Learn more ⬇️ Literature sources:  de Bastos  M, Stegeman  BH, Rosendaal  FR, Van Hylckama Vlieg  A, Helmerhorst  FM, Stijnen  T, Dekkers  OM. Combined oral contraceptives: venous thrombosis. Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No.: CD010813. DOI: 10.1002/14651858.CD010813.pub2. Accessed 16 June 2021.  Douxfils J, Morimont L, Bouvy C. Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk. Semin Thromb Hemost. 2020 Nov;46(8):872-886. doi: 10.1055/s-0040-1714140. Epub 2020 Oct 20. PMID: 33080636.  Abou-Ismail MY, Citla Sridhar D, Nayak L. Estrogen and thrombosis: A bench to bedside review. Thromb Res. 2020 Aug;192:40-51. doi: 10.1016/j.thromres.2020.05.008. Epub 2020 May 11. PMID: 32450447; PMCID: PMC7341440.  Morimont L, Dogné JM, Douxfils J. Letter to the Editors-in-Chief in response to the article of Abou-Ismail, et al. entitled "Estrogen and thrombosis: A bench to bedside review" (Thrombosis Research 192 (2020) 40-51). Thromb Res. 2020 Sep;193:221-223. doi: 10.1016/j.thromres.2020.08.006. Epub 2020 Aug 5. PMID: 32798963.  Visit QUALIblood website: https://www.qualiblood.eu   Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.   

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in haemostasis.  In today episode, our co-host Cécile Hourquet, Product Line Manager for eSolutions and services, will come to talk about the digitalization of the laboratories.    As usual, don't forget to send any question you may have to ask@stago.com, we will be glad to answer to it.    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice. 

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in coagulation.  In today episode, Stephen MacDonald, Principal Clinical Scientist from Cambridge University Hospital, will demystify the process of Measurement Uncertainty determination.    As usual, don't forget to send any question you may have to ask@stago.com, we will be glad to answer to it.     To learn more:  Go on the websites 

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in haemostasis.  In today episode, our expert Marisa Ninivaggi, research project leader at Synapse research institute, will explain us what is thrombin generation.  As usual, don’t forget to send any question you may have to Ask@stago.com, we will be glad to answer to it.  Learn more  

Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in haemostasis.  In today episode, our expert Rachael Lamma, a member of our US technical support specialist team, will explain how to handle lot conversion in the daily laboratory organization.   As usual, don’t forget to send any question you may have to Ask@stago.com, we will be glad to answer to it. Learn more 

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation.  In today’s episode, our expert our expert François Depasse, Clinical development Director, will help us to clarify when thrombophilia testing is appropriate and how to perform it according to international standards.   As usual, don’t forget to send any question you may have to ask@stago.com we will be glad to answer to it.  Literature sources:  https://www.cochranelibrary.com/advanced-search/mesh;jsessionid=DED8CB403679070FD38E81E38E5A7ECA accessed March 17, 2021  Montagnana M, Lippi G, Danese E. An Overview of Thrombophilia and Associated Laboratory Testing. Methods Mol Biol. 2017;1646:113-135. doi: 10.1007/978-1-4939-7196-1_9.  Merriman L, Greaves M. Testing for thrombophilia: an evidence-based approach. Postgrad Med J. 2006 Nov;82(973):699-704. doi: 10.1136/pgmj.2006.048090.   Gruel Y et al, Thrombophilia testing: Proposals of the 2020 GFHT. Rev Francoph Hémost Thromb 2020 ; 2 (3) : 93-126  Delluc A, Antic D, Lecumberri R, Ay C, Meyer G, Carrier M. Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2017 Oct;15(10):2076-2079. doi: 10.1111/jth.13791. Epub 2017 Aug 29. Erratum in: J Thromb Haemost. 2017 Dec;15(12 ):2471.  D'Astous J, Carrier M. Screening for Occult Cancer in Patients with Venous Thromboembolism. J Clin Med. 2020 Jul 27;9(8):2389. doi: 10.3390/jcm9082389  Connors JM. Thrombophilia Testing and Venous Thrombosis. N Engl J Med. 2017 Sep 21;377(12):1177-1187. doi: 10.1056/NEJMra1700365.  National Institute for Health and Care Excellence. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. NG 158, London 2020  De Stefano V, Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. Thromb Haemost. 2013 Oct;110(4):697-705. doi: 10.1160/TH13-01-0011.  Moll, S. Who should be tested for thrombophilia?. Genet Med 13, 19–20 (2011).  Cooper PC, Pavlova A, Moore GW, Hickey KP, Marlar RA. Recommendations for clinical laboratory testing for protein C deficiency, for the subcommittee on plasma coagulation inhibitors of the ISTH. J Thromb Haemost. 2020 Feb;18(2):271-277. doi: 10.1111/jth.14667.   Marlar RA, Gausman JN, Tsuda H, Rollins-Raval MA, Brinkman HJM. Recommendations for clinical laboratory testing for protein S deficiency: Communication from the SSC committee plasma coagulation inhibitors of the ISTH. J Thromb Haemost. 2021 Jan;19(1):68-74. doi: 10.1111/jth.15109.  Van Cott EM, Orlando C, Moore GW, Cooper PC, Meijer P, Marlar R; Subcommittee on Plasma Coagulation Inhibitors. Recommendations for clinical laboratory testing for antithrombin deficiency; Communication from the SSC of the ISTH. J Thromb Haemost. 2020 Jan;18(1):17-22.   Devreese KMJ, de Groot PG, de Laat B, Erkan D, Favaloro EJ, Mackie I, Martinuzzo M, Ortel TL, Pengo V, Rand JH, Tripodi A, Wahl D, Cohen H. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2020 Nov;18(11):2828-2839. doi: 10.1111/jth.15047.  Sevenet PO, Cucini V, Hervé T, Depasse F, Carlo A, Contant G, Mathieu O. Evaluation of DOAC Filter, a new device to remove direct oral anticoagulants from plasma samples. Int J Lab Hematol. 2020 Oct;42(5):636-642. doi: 10.1111/ijlh.13267.  Exner T, Michalopoulos N, Pearce J, Xavier R, Ahuja M. Simple method for removing DOACs from plasma samples. Thromb Res. 2018;163:117-122  Related podcasts:   S1E13 - The Lupus Anticoagulant Diagnosis Work up - https://www.podcastics.com/episode/54015/link/ ____________________________________________________________________________________________________________ Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice. 

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation.  In today’s episode, our expert Paul, in honor of the upcoming World Hemophilia Day, taking place April 17, will return to our podcast series to cover clinical laboratory testing approaches for patients with inherited or acquired haemophilia.   Literature sources:  Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D, Herr C, et al.; Data and Demographics Committee of the World Federation of Hemophilia. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019 Oct 15;171(8):540-546.   Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al.; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020 Aug;26 Suppl 6:1-158.   College of American Pathologists. Hematology and Coagulation Checklist. Northfield, IL: College of American Pathologists; 2020.    Related podcasts:   S2E4 – how to determine factor levels in hemophilia - https://www.podcastics.com/episode/62593/link/  ____________________________________________________________________________________________________________ Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice. 

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today episode, our expert Thomas, is covering with us the usages of APTT testing. Literature sources: Toulon, P., Eloit, Y., Smahi, M., Sigaud, C., Jambou, D., Fischer, F. and Appert‐Flory, A. (2016), In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies. Int. Jnl. Lab. Hem., 38: 389-396. https://doi.org/10.1111/ijlh.12499 CLSI One-stage Prothrombin Time (PT) test and Activated Partial Thromboplastin Time (APTT) test; Approved guideline - second edition. CLSI document H47-A2 Wayne, PA: Clinical and Laboratory Standard Institute, 2008 Levy JH, Szlam F, Wolberg AS, Winkler A. Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing. Clin Lab Med. 2014 Sep;34(3):453-77. doi: 10.1016/j.cll.2014.06.005 Kitchen S, Jennings I, Woods TA, Preston FE. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol. 1996 Jan;49(1):10-4. doi: 10.1136/jcp.49.1.10. Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother. 2004 Sep;38(9):1383-8. doi: 10.1345/aph.1D565. Gouin-Thibaut I, Martin-Toutain I, Peynaud-Debayle E, et al. Monitoring unfractionated heparin with APTT: a French collaborative study comparing sensitivity to heparin of 15 APTT reagents. Thrombosis Research. 2012 May;129(5):666-667. DOI: 10.1016/j.thromres.2011.11.016. Triplett DA. Screening for the lupus anticoagulant. Ricerca in Clinica E in Laboratorio. 1989; 19-379-89 Denis-Magdelaine A et al; Sensitivity of sixteen APTT reagents for the presence of anticoagulant. Haemostasis 1995; 25:98-105/ Rozen L, Copette F, Noubouossie DF, Demulder A. Evaluation of three APTT reagents in a routine laboratory: toward a compromise. Clin Lab. 2013;59(7-8):921-4. doi: 10.7754/clin.lab.2012.120909 van Rossum, A.P., Vlasveld, L.T., van den Hoven, L.J.M., de Wit, C.W.M. and Castel, A. (2012), False prolongation of the activated partial thromboplastin time (aPTT) in inflammatory patients: interference of C‐reactive protein. Br J Haematol, 157: 394-395. https://doi.org/10.1111/j.1365-2141.2011.08990.x Gu, J.‐M., Ramsey, P., Evans, V., Tang, L., Apeler, H., Leong, L., Murphy, J.E., Laux, V. and Myles, T. (2014), Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94‐9027) for haemophilia A. Haemophilia, 20: 593-600. https://doi.org/10.1111/hae.12374 Hillarp A, Bowyer A, Ezban M, Persson P, Kitchen S. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study. Haemophilia. 2017 May;23(3):458-465. doi: 10.1111/hae.13168. Ezban M, Hansen M, Kjalke M. An overview of turoctocog alfa pegol (N8-GP; ESPEROCT® ) assay performance: Implications for postadministration monitoring. Haemophilia. 2020;26(1):156-163. doi:10.1111/hae.13897 Related podcasts: Ask Stago S1E11: UFH monitoring: APTT or Anti-Xa? https://www.podcastics.com/podcast/episode/11-%E2%80%93-monitoring-of-ufh-aptt-or-anti-xa-41033/ Ask Stago S1E13: The Lupus Anticoagulant Diagnosis work up: https://www.podcastics.com/podcast/episode/13-the-lupus-anticoagulant-diagnosis-work-up%C2%A0-54015/ ____________________________________________________________________________________________________________ Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in hemostasis. In today episode, our expert Pierre Bourgeat, will discuss about the Prothrombin time reagent characteristics with a specific focus on the ISI and the type of activators. As usual, don’t forget to send any question you may have to Ask@stago.com, we will be glad to answer to it. To learn more: Listen to our podcast about MNPT determination: #7 How to determine the mean normal prothrombin time View the Webinar of Ian Jenning on stagowebinar.com Literature: Lusher, J. Screening and diagnosis of coagulation disorders. Am. J. Obstet. Gynecol. 1986; 175:778-783 Riley, R., Rowe, D., & Fisher, L. Clinical utilization of the international normalized ratio (INR). J. Clin. Lab. Anal. 2000; 14:101-114 WHO Technical Report Series, No. 610, 1977 Ian Jennings, PT/INR measurement for the management of VKA therapy, Stagowebinar.com, 3 October 2017 WHO Technical Report Series, No. 979, 2013 CLSI One-stage Prothrombin Time (PT) test and Activated Partial Thromboplastin Time (APTT) test; Approved guideline - second edition. CLSI document H47-A2 Wayne, PA: Clinical and Laboratory Standard Institute, 2008 Smith SA, Comp PC, Morrissey JH. Traces of factor VIIa modulate thromboplastin sensitivity to factors V, VII, X, and prothrombin. J Thromb Haemost. 2006;4(7):1553-1558. ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today episode, our expert Vicki, will give you all her tips to collect and prepare you sample in the best way. From sample, material or storage be sure to provide valid sample to your lab. A podcast to share with your colleague, nurses or any person in charge of the preparation of the sample in your facility. As usual, don’t forget to send any question you may have to Ask@stago.com, we will be glad to answer to it. To learn more: Continue with our podcast dedicated to the HIL pre-analytical check https://www.podcastics.com/podcast/episode/9-how-to-manage-hil-samples-in-the-coagulation-laboratory-37748/ Literature: Stability of coagulation proteins in frozen plasma. B. Woodhams, O. Girardot, MJ Blanco and Y.Gourmelin, Blood coagulation and fibrinolysis 2001, 12:229-236 Effects of storage time and temperature on coagulation tests and factors in fresh plasma Limin Feng, Ying Zhao, Hongcan Zhao & Zhexin Shao Scientific Reports 4, Article number: 3868 (2014) doi:10.1038/srep03868 Quality Standards for Sample Collection in Coagulation Testing Giuseppe Lippi, M.D. 1 Gian Luca Salvagno, M.D. 2 Martina Montagnana, M.D. 2 Gabriel Lima-Oliveira, M.D. 2 Gian Cesare Guidi, M.D. 2 Emmanuel J. Favaloro, Ph.D., M.A.I.M.S., F.F.Sc. (RCPA) 3 Semin Thromb Hemost 2012;38:565–575. Quality in Laboratory Hemostasis and Thrombosis. S.Kitchen, JD Olson, E.Preston. Wiley-Blackwell 2009 Quality Standards for Sample Processing,Transportation, and Storage inHemostasis Testing Dorothy M. Adcock Funk M.D., Giuseppe Lippi M.D., Emmanuel J. Favaloro Ph.D., Semin Thromb Hemost 2012;38:576–585. Pre-analytical Variables in Coagulation Testing Associated With Diagnostic Errors in Hemostasis Emmanuel J. Favaloro, PhD, MAIMS, FFSc (RCPA); Dorothy M. (Adcock) Funk, MD; Giuseppe Lippi, MD DisclosuresLab Med. 2012;43(2):1-10.  Effects of haemolysis, icterus and lipaemia on coagulation tests as performed on Stago STA-Compact-Max analyser, A. WOOLLEY, J.-L. GOLMARD, S. KITCHEN, 2016 John Wiley & Sons Ltd, Int. Jnl. Lab. Hem. Recommandation préanalytiques en hémostase; GFHT 2017-2018 CLSI Collection, Transport and Processing of Blood Specimens for Testing Plasma-based Coagulation Assays and Molecular Hemostasis Assays; Approved Guideline – Fifth Edition. CLSI Document H21-A5; Wayne, PA: Clinical and Laboratory Standards Institute; 2008 Alesci S, Borggrefe M, Dempfle CE. Effect of freezing method and storage at -20⁰C and -70⁰C on prothrombin time, aPTT and plasma fibrinogen levels. Thromb Res. 2009;124(1):121-126. van den Besselaar AM, Witteveen E, van der Meer FJ. Long-term stability of frozen pooled plasmas stored at -70°C, -40°C, and -20°C for prothrombin time and International Normalized Ratio (INR) assessment. Thromb Res. 2013 Apr;131(4):349-51. doi: 10.1016/j.thromres.2013.01.020. Epub 2013 Feb 12. PMID: 23411127.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today episode, our expert Alex, will discuss with us how to determine factor levels in hemophilia patients. Literature sources: Alfonso Iorio,Jeffrey S. Stonebraker, Hervé Chambost, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med.2019;171:540-546. [Epub ahead of print 10 September 2019]. doi:10.7326/M19-1208 Blanchette, VS, Key, NS, Ljung, LR, Manco‐Johnson, MJ, van Den Berg, HM, Srivastava, A, for the Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12: 1935– 9. Baker, P., Platton, S., Gibson, C., Gray, E., Jennings, I., Murphy, P., Laffan, M. and (2020), Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Br. J. Haematol., 191: 347-362. https://doi.org/10.1111/bjh.16776 CLSI, Determination of coagulation factor activities using the one-stage clotting assays. 2nd edition. CLSI guideline H48. Wayne PA: Clinical and Laboratory Standards Institute, 2016. College of American Pathologists. Hematology and Coagulation Checklist. Northfield, IL: College of American Pathologists; 2018 Riley PW, Gallea B, Valcour A. Development and implementation of a coagulation factor testing method utilizing autoverification in a high‑volume clinical reference laboratory environment. J Pathol Inform 2017;8

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today episode, our expert Tara Simpson, will cover with us how to establish and control an assay reference range. Literature sources: Henny J. Établissement et validation des intervalles de référence au laboratoire de biologie médicale. Ann Biol Clin 2011 ; 69(2) : 229-37 doi:10.1684/abc.2011.0537 Gardiner, C, Coleman, R, de Maat, MPM, et al. International Council for Standardization in Haematology (ICSH) laboratory guidance for the evaluation of haemostasis analyser‐reagent test systems. Part 1: Instrument‐specific issues and commonly used coagulation screening tests. Int J Lab Hematol. 2020; 00: 1– 15. https://doi.org/10.1111/ijlh.13411 CLSI. EP28-A3C Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory: Approved Guideline. 3rd ed. Wayne, PA: CLSI; 2008;28:1‐76 Castellone DD. Establishing reference intervals in the coagulation laboratory. Int J Lab Hematol. 2017;39(Suppl 1):121-127 CLSI. Measurement procedure comparison and Bias Estimation Using Patient samples. 3rd ed. CLSI guideline EP09c. Wayne PA: Clinical and Laboratory Standards Institute; 2018

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In today episode, our expert Draga, will give you all her tips to have the perfect calibration.

Welcome to Ask Stago, the weekly podcast about hemostasis. This week, Cécile Hourquet and Audrey Carlo will discuss about viscoelastic testing and the usage of it with our expert Wim Houdijk. Literature: Hartert H. Blutgerinnungsstudien mit der Thrombelastographie, einem neuen Untersuchungsverfahren.Klin Wochenschr. 1948;26:577-583. Sayce AC, Neal MD, Leeper CM. Viscoelastic monitoring in trauma resuscitation Transfusion. 2020;60 (Suppl 6):S33-S51. Agarwal S, Abdelmotieleb M. Viscoelastic testing in cardiac surgery. Transfusion. 2020;60 (Suppl 6):S52-S60. Tetsuro Sakai.Viscoelastic testing in liver transplantation. Transfusion. 2020;60 (Suppl 6):S61-S69. Waters JH. The role of viscoelastic testing in the management of the parturient. Transfusion. 2020;60 (Suppl 6):S70-S74. Carll T, Wool GD. Basic principles of viscoelastic testing. Transfusion. 2020;60 (Suppl 6):S1-S9. Cohen T, Haas T, Cushing MM. The strengths and weaknesses of viscoelastic testing compared to traditional coagulation testing. Transfusion. 2020;60 (Suppl 6):S21-S28. Meco M, Montisci A, Giustiniano E, Greco M, Pappalardo F, Mammana L, Panisi P, Roscitano C, Cirri S, Donatelli F, Albano G. Viscoelastic blood tests use in adult cardiac surgery: meta-analysis, meta-regression, and trial sequential analysis. J Cardiothorac Vasc Anesth. 2020;34:119-127. Allen TW, Winegar D, Viola F. The Quantra system and SEER sonorheometry. In Moore HB, et al. (eds.), Trauma induced coagulopathy. Springer Nature Switzerland AG 2021, pages 693-704.

Welcome to Ask Stago, the weekly podcast for Hemostasis laboratory professionals.   This week, with our expert Paul Riley, Scientific Business Development Manager, Cécile Hourquet and Audrey Carlo will cover the usage of fibrin related markers in the diagnosis of disseminated intravascular coagulopathy.   Litterature: Baglin T. Disseminated intravascular coagulation: diagnosis and treatment. BMJ 1996; 312: 683-7 Iba T, Di Nisio M, Thachil J, Wada H, Asakura H, Sato K, Kitamura N, Saitoh D. Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. Crit Care. 2016 Sep 14;20:287 Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001 Nov;86(5):1327-30 JAAM; Iba T, Di Nisio M, Thachil J, Wada H, Asakura H, Sato K, Kitamura N, Saitoh D. Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. Crit Care. 2016 Sep 14;20:287 Boral BM, Williams DJ, Boral LI. Disseminated Intravascular Coagulation. Am J Clin Pathol 2016; 146: 670-80 Wada H, Sakuragawa N. Are fibrin-related markers useful for the diagnosis of thrombosis? Semin Thromb Hemost 2008; 34: 33-8 Toh JMH, Ken-Drorb G, Downey D, Abram ST. The clinical utility of fibrin-related biomarkers in sepsis Blood Coagulation and Fibrinolysis 2013, 24:00–00 Gris JC, Cochery-Nouvellon E, Bouvier S, Jaber S, Albanese J, Constantin JM, Orban JC, Morel J, Leone M, Deras P, Elotmani L, Lavigne-Lissalde G, Lefrant JY. Clinical value of automated fibrin generation markers in patients with septic shock: a SepsiCoag ancillary study. Br J Haematol. 2018 Nov;183(4):636-647 (Singh N, Prasad Pati H, Tyagi S, Datt Upadhyay A, Saxena R. Evaluation of the Diagnostic Performance of Fibrin Monomer in Comparison to D-Dimer in Patients With Overt and Nonovert Disseminated Intravascular Coagulation. Clin Appl Thromb / Hemost 2015; 1-6.). (Park KJ, Kwon EH, Kim HJ, Kim SH. Evaluation of the diagnostic performance of fibrin monomer in disseminated intravascular coagulation. Korean J Lab Med. 2011; 31: 143-7.).

Welcome to Ask Stago, weekly podcast dedicated to providing expert answers to your expert questions in coagulation. This week, thanks to their expert Alexandre Rousseaux, Cécile Hourquet and Audrey Carlo will question how to be more productive in the lab using a workcell.

Welcome to Ask Stago, the weekly podcast dedicated to providing expert answers to your expert questions in coagulation.   This week, with our expert Lisa Gannon, product line manager, Cécile Hourquet and Audrey Carlo will question how to accurately perform an Lupus Anticoagulant diagnosis work up in the laboratory.   Sources: Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306 Devreese KMJ, Ortel TL, Pengo V, de Laat B; Subcommittee on Lupus anticoagulant/Antiphospholipid antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16: 809-813 CLSI Laboratory testing for the Lupus anticoagulant - Approved Guideline. CLSI document H60-A. Wayne, PA; 2014. Devreese, KMJ, de Groot, PG, de Laat, B, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020; 18: 2828– 2839. https://doi.org/10.1111/jth.15047 V. Chantarangkul, F. Peyvandi, A. Tripodi, et al., Effect of different methods for outlier detection and rejection when calculating cut off values for diagnosis of lupus anticoagulants, Thrombosis Research (2018), https://doi.org/10.1016/j.thromres.2020.03.018 CLSI Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory: Approved guideline Third edition. CLSI document C28-A3- Wayne, PA; 2008

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. On today’s episode, thanks to our expert Andres Ramirez, discover the part 2 of our series “how to be more productive” with a special episode about Lean and Six sigma workflow analysis.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In our episode this week, we will discuss with François Depasse, our Clinical Development Director, about the monitoring of UFH and the appropriate tool to do it: APTT or anti-Xa activity? Sources: Johnson EA, Mullboy B. The molecular weight range of commercial heparin preparations. Carbohydr Res 1976; 51: 119-127 Hirsh J, Raschke R, Heparin and Low-molecular-weight heparin : the Seventh ACCP Conference on Antithrombotic and thrombolytic therapy. CHEST 2004; 126 (suppl 3): 188S-203S. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972 Aug 17;287(7):324-7. doi: 10.1056/NEJM197208172870703. PMID: 5041701. Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost. 2006 Nov;96(5):547-52. Frugé KS, Lee YR. Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring. Am J Health Syst Pharm. 2015 Sep 1;72(17 Suppl 2):S90-7. Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012 Jun;32(6):546-58. doi: 10.1002/j.1875-9114.2011.01049.x. Epub 2012 Apr 24.

Welcome to Ask Stago, the weekly podcast for Hemostasis laboratory professionals. In today’s episode, with our expert Draga Tchipeva, international application specialist, Cécile Hourquet and Audrey Carlo will start questioning how we can help the laboratory to become more productive with some middleware solutions: rules engines.

Welcome to Ask Stago, the weekly podcast for Hemostasis laboratory professionals. This week, with our expert Frédéric Brutto, product line manager, Cécile Hourquet and Audrey Carlo will question HIL interferences and how the coagulation laboratory can handle them. Sources: Lippi G et al., Interference of blood cell lysis on routine coagulation testing. Arch Pathol Lab Med. 2006;130(2):181-4 Woolley A et al., Effects of haemolysis, icterus and lipaemia on coagulation tests as performed on Stago STA-Compact-Max analyser. Int J Lab Hematol. 2016; 38(4): 375-88 Plebani M, Quality Indicators to Detect Pre-Analytical Errors in Laboratory Testing, Clin Biochem Rev 2012; 3: 85-88. Salvagno GL et al, Prevalence and type of pre-analytical problems for inpatients samples in coagulation laboratory, J Eval Clin Pract. 2008 ;14(2):351-3. CLSI Hemolysis, Icterus, and Lipemia/Turbidity Indices as Indicators of Interference in Clinical Laboratory Analysis; Approved Guideline. CLSI document C56-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2012 CLSI Collection, Transport and Processing of Blood Specimens for Testing Plasma-based Coagulation Assays and Molecular Hemostasis Assays; Approved Guideline – Fifth Edition. CLSI Document H21-A5; Wayne, PA: Clinical and Laboratory Standards Institute; 2008

Welcome to Ask Stago, the weekly podcast for Hemostasis laboratory professionals In today’s episode, with Lydie Nicoud, Director of Design and Biological Applications development, Cécile Hourquet and Audrey Carlo will try to better understand sensitivity and specificity of a diagnostic test, through some examples. Sources: CLSI, Quantitative D-dimer for the Exclusion of Venous Thromboembolic Disease, CLSI document H59-A, Wayne PA; Clinical Laboratory Standards Institute 2011 Valentine Minet, Jean-Michel Dogné, and François Mullier, Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review Molecules 22, no. 4 (April 11, 2017): 617, https://doi.org/10.3390/molecules22040617. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392. doi:10.1182/bloodadvances.2018024489 Nagler M, Bachmann LM , ten Cate H, ten Cate-Hoek A, Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2016; 127 (5): 546–557. doi: https://doi.org/10.1182/blood-2015-07-661215

Welcome to Ask Stago, the weekly podcast for Hemostasis laboratory professionals.  In today’s episode, we will provide you our best tips and tricks to calculate the mean normal prothrombin time for INR assay. To do so, Cécile Hourquet and Audrey Carlo are pleased to welcome Arnaud Rouvière, Manager of the International Application Engineer team of Stago. Source: WHO technical report series ; no. 979, 2013